NSCLCs have acquired resistance to EGFR inhibitors eventually, with median time to disease progression of about 10 months. [3] [4] [5] [6] The primary cause of death from lung cancer was cancer cell invasion to the surrounding tissues and metastasis to distal organs. 7 It has been observed that tumours are more likely to metastasize after EGFR-TKI resistance. Some of the known mechanisms for drug resistance included a subsequent mutation in the EGFR kinase domain (T790M) and the amplification of MET receptor tyrosine kinase. [8] [9] [10] [11] [12] Little is known why the resistant cells are prone to metastasize. Metastasis is a very complex process that involves the alteration of the micro-environment, the interactions of cell-tocell and cell-to-matrix, the loss of adhesion, and migration and invasion. 13, 14 Conversion from well-differentiated cells to a stem cell-like phenotype was considered to be associated with a higher metastasis potential. [15] [16] [17] [18] [19] CD146 (or MCAM) is a key cell adhesion protein belonging to the superfamily of immunoglobulin. It was initially reported as a melanoma marker promoting melanoma growth and metastasis. [20] [21] [22] We and other research teams reported that the high expression of CD146 is associated with lymph node metastasis and poor prognosis in surgically treated NSCLCs. [23] [24] [25] However, the role and the mechanism of CD146 in tumour progression and metastasis processes still remained unknown. In melanoma, the over-expression of CD146 could upregulate Id-1 by the down-regulation of ATF-3, which was a transcription inhibitor of Id-1, contributing to melanoma metastasis. 26 Over-expressed CD146 increased the EMT process via the up-regulation of the transcriptional factor Slug, which controlled the transcription of various EMT-related elements, such as MMP-9. 27, 28 Recently, increasing evidence suggests that CD146 was the mesenchymal stem cell marker. 29, 30 In breast cancer, CD146 was found as an epithelial-mesenchymal transition inducer to promote cell migration and cancer stem cell-like transition, particularly for triple-negative breast cancer. 27 The function of CD146 in colorectal cancer is thought to be a suppressor of tumorigenesis and cancer stemness by inactivating the canonical Wnt/β-catenin cascade, 31 which is undefined in lung cancer.
Here, we reported that CD146 could promote stemness phenotype in EGFR-TKI-resistant cells of lung cancer and increase cell migration for the first time. And this process could be blocked by CD146 siRNA, demonstrating its important role and potential therapeutic target in lung cancer.
| MATERIALS AND METHODS

| TKI-sensitive and resistant cell lines
The human lung NSCLC cell line H1650 was purchased from the Type Culture Collection of the Chinese Academy of Sciences, Shanghai, China (http://cellresource.cn/index.aspx). The human lung adenocarcinoma cell line PC9 was obtained from Professor Wu Yilong (Guangdong Provincial People's Hospital). The erlotinib-resistant cell line (H1650ER) was established by treating H1650 cells with erlotinib (10 µM) for 4 months. The gefitinib-resistant cell line (PC9GR) was established by exposing the parental cells to increasing concentrations of Gefitinib, up to 2 µM for 6 months. All cells were cultured in RPMI medium 1640 (Hyclone, Logan, UT, USA) containing 10% FBS (Gibco, Carlsbad, CA, USA) in humidified 5% CO 2 incubator at 37°C. All experiments were performed after erlotinib-abandoned culture for two weeks.
| Antibodies and reagents
The following antibodies were used in this study: rabbit anti-CD146 antibody (ab75769, Abcam, Cambridge, USA) and rabbit anti-β-catenin antibody (8480, CST). Rabbit anti-GAPDH antibody, Alexa Fluor 488-conjugated affinipure goat anti-rabbit IgG(H+L) and peroxidase-conjugated affinipure goat anti-rabbit IgG(H+L) were purchased from ZSGB-BIO, China. Erlotinib and gefitinib were obtained from Selleck (S7786, Houston, USA). MicroBeads and 60 μL buffer were added to the cells, mixed well and incubated for 15 minutes at 4°C. The column was placed in the magnetic field of a suitable MACS Separator, and was prepared by rinsing with 3 mL of buffer. The cells were transferred into the column and washed with 3 × 3 mL of buffer. The column was removed from the separator and placed on a suitable collection tube. Five millilitres of the buffer was pipetted onto the column, immediately flushing out the magnetically labelled cells by firmly pushing the plunger into the column and centrifuged for 800 rpm to obtain positive cells.
| Cell Counting Kit-8 assay
The inhibition rate of the cells after being treated with erlotinib/ gefitinib was tested by the Cell Counting Kit-8 Assay (CCK-8, Solarbio, Beijing, China) assay. Cells were harvested with trypsin and resuspended in a medium and seeded in a 96-well plate, 3000 cells per well. After incubation at 37°C and 5% CO 2 for 24 hours, different concentrations of erlotinib/gefitinib (200 µL/well) were added into the designated wells. The plated were incubated for 72 hours at 37°C and 5% CO 2; 10 µL CCK-8 solution was added to each well, and then incubated for another 2 hours. Finally, the absorbance was determined at 450 nm by the Opsys microplate reader (Dynex Technologies, Chantilly, Virginia). The concentrations required to inhibit growth by 50% (IC50) were calculated by the SPSS software.
| Transwell assay (high-content screening) for cell invasion
For the transwell assay, 1 × 10 4 cells were plated in the upper chamber of a transwell 24-well plate with serum-free medium, and the lower chamber contained 20% FBS medium. After 48 hours, the medium was removed and the chambers were washed twice with PBS. Non-invading cells were removed from the upper surface of the membrane by scrubbing with cotton tipped swabs; meanwhile, the invading cells were fixed with 4% paraformaldehyde for 15 minutes. Then the chambers were stained with DAPI dihydrochloride for 10 minutes. All fields for each chamber were photographed and the invading cells were counted via a High-Content Screening Applications (Thermo Fisher, Rockford, USA). The results were analysed using the Thermo Scientific HCS Studio software.
| Cell migration by scratch assay
A uniform cell-free area in a 6-well plate was created by scratching the confluent monolayer of cells with a plastic micropipette tip. The plate was washed with PBS, added into each well with serum-free medium and incubated at 37°C. The wound area was inspected at different time intervals (0, 24 hours, 48 hours) to determine the distance migrated by the cells.
| Western blot for measuring CD146 and β-catenin
After 48 hours of incubation, total protein lysates were prepared from cultured cells using the RIPA buffer (25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% NP-40, 1% deoxycholate, 1% SDS) plus protease inhibitors. The protein concentration was determined using the BCA Protein Assay. Equal amounts of cell lysates were denatured, separated by SDS− PAGE and transferred to 0.2-µm nitrocellulose membranes. After blocking with PBS containing 5% nonfat dry milk, the membranes were incubated overnight at 4°C with primary antibodies, followed by incubation with horseradish peroxidase-conjugated secondary antibodies. The immunoblots were visualized by an enhanced chemiluminescence kit from Thermo Fisher. GAPDH protein was used as internal control. Quantification was performed by ImageJ.
| Small interfering RNA (siRNA) transfection
The sequence of CD146 si-RNA is: forward, 5′-CCA GCU CCG CGU CUA CAA AdTdT-3′; reverse, 5′-UUU GUA GAC GCG GAG CUG GdTdT-3′. 2×10 5 cells were plated in 6-well plates. After incubation at 37°C and 5% CO 2 for 24 hours, the culture medium was replaced with fresh serum-free medium. Transfection was performed using Lipofectamine 2000 (Invitrogen) at a 2:1 ratio (2 μL of Lipofectamine 2000 per 1 μg of nucleic acids) with siRNA at 20 nM final concentration after 20 minutes of incubation at room temperature. The cells were incubated for 6 hours, and then the medium containing the transfection mixture was replaced with a fresh culture medium. After culturing for 48 hours, the cells were harvested for western blot and RT-PCR.
| CD146 and β-catenin detected by immunofluorescence
Cells were plated on slides cultured in 24-well plates and then the cells were washed with PBS, fixed in acetone/methanol (1:1) for 30 seconds, permeabilized with 0.1% Triton X-100, blocked with 5% normal goat serum for 60 minutes at 37°C and then incubated with primary antibodies at 4°C for one night; then they were washed with PBS, incubated with green fluorescence second antibody and then stained with DAPI. Coverslips were mounted and the slides were subsequently examined with a laser scanning confocal microscope (Olympus FLUOVIEW FV 1000) with an Olympus IX81 digital camera using 20/0.75 numeric aperture objective.
| Quantitative real-time PCR
Total RNA was collected from cultured cells and purified using Trizol reagent following the manufacturer's instructions (Takara). Total RNA (2 μg) was subjected to a reverse transcriptase reaction using the Improm-II Reverse Transcriptase kit (Thermo Fisher). cDNA corresponding to approximately 1% of the RNA was used in three replicates for quantitative PCR with the SYBR GREEN (Roche) labelling. Oligonucleotides for real-time quantitative PCR were: CD146: forward, 5′-GCT GCC CAG TGG GAA CCA CA-3′, reverse, 5′-ATC ATG GTG TCC AAG TTC CAG GC-3′; CD133: forward, 5′-CAC TAC CAA GGA CAA GGC GTT C-3′, reverse, 5′-CAA CGC CTC TTT GGT CTC CTT G-3′; SOX2: forward, 5′-TAC AGC ATG TCC TAC TCG CAG-3′, reverse, 5′-GAG GAA GAG GTA ACC ACA GGG-3′; Nanog: forward, 5′-AGG CAA ACA ACC CAC TTC T-3′, reverse, 5′-TCA CAC CAT TGC TAT TCT TCG-3′; Oct4: forward, 5′-TAT TCA GCC AAA CGA CCA TCT-3′, reverse, 5′-TCA GCT TCC TCC ACC CAC TT-3′; CD24: forward, 5′-CTC CTA CCC ACG CAG ATT TAT TC-3′, reverse, 5′-AGA GTG AGA CCA CGA AGA GAC-3′; CD44: forward, 5′-GTG CTA CTT CAG ACA ACC ACA A-3′, reverse, 5′-GTA CTA CTA GGA GTT GCC TGG AT-3′; GAPDH: forward, 5′-AGG TCG GAG TCA ACG GAT TTG-3′, reverse, 5′-GTG ATG GCA TGG ACT GTG GT-3′.
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| Microsphere formation assay for stemness phenotype
The microsphere formation assay was done on ultra-low attachment 96-well plates (Corning, New York, USA) at a density of 1000 viable cells/mL and grown in a serum-free Dulbecco's modified Eagle medium/F12 (Sigma, St. Louis, MO, USA) supplemented with B27 (Invitrogen, Carlsbad, CA, USA), 20 ng/ mL of EGF and 20 ng/mL of bFGF (Invitrogen, Carlsbad, CA, USA), and 4 μg/mL of heparin (Wanbang, Suzhou, China). The cells were allowed to form spheroids for 10 days, and the number of spheres was counted through a microscope.
| Data statistics
The values were expressed as mean ± SD. Statistical analysis was done by two independent sample t tests. The differences were considered to be statistically significant if P < 0.05.
| RESULT
| The expression of CD146 increased in EGFR-TKI resistant cell lines
To investigate the metastasis mechanisms of NSCLC with EGFR-TKI resistance, we established an acquired erlotinib-resistant cell line, H1650ER, and an acquired gefitinib-resistant cell line, PC9GR, derived from the parental cell lines H1650 and PC9, respectively, as described previously. To validate erlotinib/gefitinib resistance in H1650ER/PC9GR, the IC50 of cells was detected by the CCK8 assay at different erlotinib/ gefitinib concentrations for 72 hours. The IC50 was 2.43 µM for parental H1650 cells and 5.08 µM for H1650ER cells (low resistance to erlotinib).The IC50 for parental PC9 cells and PC9GR cells was 0.05 µM and 7.05 µM, respectively, indicating PC9GR cells' high resistance to gefitinib ( Figure 1A,B) . We analysed the expression of CD146 by both the mRNA and protein levels in resistant cells and parental cells. The mRNA of CD146 was more than 5 times higher in H1650ER cells than in H1650 cells by RT-PCR ( Figure 1D) . Similarly, CD146 protein increased in H1650ER ( Figure 1C,E) . However, CD146 level in PC9GR and PC9 was not clearly different. CD146 + PC9GR cells selected from PC9GR cells by MACS showed that both the mRNA and protein levels of CD146 were up-regulated when compared with the PC9 cell line ( Figure 1C,D) .
| Stemness phenotype-related genes increased while β-catenin decreased in H1650ER and PC9GRs
As CD146 increased in the resistant cells, we were interested in the expression of stemness phenotype-related genes, such as Sox-2, Nanog, OCT4, CD133, CD44 and CD24. Our data showed that Sox-2, Nanog, OCT4, CD133 and CD44 were all up-regulated at the mRNA level in H1650ER and PC9GRs, while CD24 was down-regulated when compared with their respective parental cells (Figure 2A,B) . Furthermore, the results of the western blot and immunofluorescence indicated that β-catenin was decreased in H1650ER and PC9GRs as compared with H1650 and PC9 cells, respectively ( Figure  2C -E).
| CD146 over-expression induced the up-regulation of stemness phenotype genes but suppressed the expression of β-catenin
We up-regulated the CD146 expression in H1650 and PC9 cells by using a CD146 over-expression slow virus system, and NC (negative control) as a control. As shown in Figure  3A , CD146 was very lowly expressed in H1650 and PC9 cell lines and transfection boosted its expression approximately 215-and 5-folds, respectively ( Figure 3A,B) . However, β-catenin expression was decreased in CD146 over-expressed groups ( Figure 3A) . By RT-PCR, the stemness phenotype genes Sox-2, Nanog, OCT4, CD133 and CD44 were all upregulated in the CD146 over-expression model, yet CD24 was decreased ( Figure 3C,D) .
| CD146 increased cell migration in resistant cell lines
To evaluate if CD146-induced stemness was associated with cell phenotypes, we performed a microsphere formation assay to evaluate cell self-renewal ability, and the transwell migration assay and the wound healing assay were used to detect cell migration. The quantity and the diameter of the microsphere in H1650ER were significantly higher than H1650 cells ( Figure 4A ), although there was no microsphere formation from PC9 and PC9GRs cells. The quantity and the diameter of the microsphere were also increased in H1650-CD146 cells compared with H1650-NC cells ( Figure 4B) . Furthermore, the number of migration cells in H1650ER and PC9GRs was much higher than their parental cells ( Figure  4C,D) . Similarly, the migration ability of H1650-CD146 and PC9-CD146 cells was higher than the control cells ( Figure  4E,F) . These results demonstrated that CD146 enhanced the stemness phenotype and migration capability of resistant cell lines.
| Knockdown of CD146 suppressed cell migration and stemness phenotype
Because the over-expression of CD146 increased migration and the stemness phenotype, we further investigated if its down-expression could lead to opposite effects. We down-regulated the CD146 expression by using siRNA targeting CD146 in H1650ER and PC9GRs cells, with NC (negative control) siRNA as a control. As shown in Figure 5A , B, CD146 expression significantly decreased, as compared to the control. Consequently, migration and the stemness phenotype were also significantly suppressed ( Figure 5C , 
| DISCUSSION
In the present study, we showed thatCD146 mediated the acquisition of stemness phenotype and enhanced tumour invasion and metastasis after EGFR-TKI resistance in lung cancer cells. The CD146 level increased in our established EGFR-TKI-resistant cell lines H1650ER and PC9GR, respectively. Zhan, et al reported that CD146 was significantly up-regulated in erlotinib-resistant H1650ER cells but not in PC9GR cells. 32 However, when we selected CD146 + cells from EGFR-TKI resistantcells by MACS, we also found that CD146's over-expression could induce increased cell migration. The previous report suggested that CD146 decreased ERα expression and activated AKT to promote tamoxifen resistance in breast cancer cells. Targeting CD146 might be a promising therapeutic strategy to overcome tamoxifen resistance in breast cancer patients. 33 We transferred CD146
siRNA into H1650ER and PC9GRs cells and observed inhibited cell migration. In resistant cells, CD146 might be induced during therapy or selected amplification from original CD146-positive lung cancer cells. We first demonstrated that the up-regulated expression of CD146 promoted tumour invasion and metastasis in EGFR-TKI resistant cells of lung cancer. All these evidences indicated that CD146 was identified as a potential marker in angiogenesis, tumour cell migration and invasion. 34, 35 An aberrant expression of CD146 was associated with patients of melanoma, breast cancer, prostatic cancer, gastric cancer and gallbladder adenocarcinoma with poor overall survival and metastasis-free survival. [36] [37] [38] Stemness phenotype genes were increased in EGFR-TKI acquired resistant cell lines, which might be regulated by CD146. Tumour stemness phenotype played a key role in tumour metastasis. 39 Cancer stem cells (CSCs) were a special subset of tumour cells, which had the ability of self-renewal and multidirection differentiation, and also could express cell surface markers, such as SOX2, Nanog, Oct4, CD44 and CD133. 40 Compelling evidences also indicated that cancer cells acquired the stem cell-like phenotype in response to tumour micro-environment, contributing to tumour proliferation, metastasis and drug resistance. [15] [16] [17] The Wnt signalling pathway regulated the cell self-renewal and multiple organ formation. β-catenin and CD146 
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Stemness phenotype and migration ability in resistance cells or CD146 over-expressed cells. A and B, Stem cell phenotype was detected by the microsphere formation assay. C-F, Cell migration was measured by the transwell assay and the scratch assay were involved in this pathway. [41] [42] [43] [44] It was shown that CD146
acted as a functional Wnt5a receptor in regulating cell migration and convergent extension by turning off the canonical Wnt signalling pathway. 45 Our data demonstrated that CD146 expression was negatively associated with β-catenin, but positively with stemness phenotype genes. β-catenin was considered as a critical regulator of the Wnt signalling pathway and has also been thought to be an important intracellular component of the e-cadherin/catenin complexes, which contributed to intercellular adhesion and signal transduction. It was involved in the development and progression, invasion and metastasis of tumour by binding to a variety of proteins. However, the downstream molecule associated with β-catenin remained undetermined in this study.
| CONCLUSION
We have demonstrated that CD146 could be an indicator of EGFR-TKI resistance in lung cancer, which enhanced the migration and metastasis of cancer cells via strengthening stemness phenotype.
